Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.C3 Jian, a clinical-stage biotechnology company, has gained FDA approval for investigational new drug application (IND) of C16G2 and expects to begin Phase I trial in July 2012.
Subscribe to our email newsletter
C16G2 is a synthetic peptide derived from C3 Jian’s proprietary Specifically Targeted Antimicrobial Peptides (STAMPS) technology which has demonstrated activity selectively targeting Streptococcus mutans, a cavity-causing organism.
The single site study which will be conducted at New York University, Bluestone Center for Clinical Research, will enroll up to 36 subjects.
C3 Jian president and CEO Todd Patrickc said, "We are eager to begin the Phase 1 Clinical Trial for this product candidate while C3J continues to advance other technologies in our pipeline."
The indication identified in the new IND is for the use of C16G2 in preventing dental caries in adults, adolescents and pediatrics, the company said.